A comprehensive view of the human UDP-glucuronosyltransferase (UGT) transcriptome is a prerequisite to the establishment of an individual's UGT metabolic glucuronidation signature. Here, we uncover the transcriptome landscape of the 10 human UGT gene loci in normal and tumoral metabolic tissues by targeted RNA next-generation sequencing. Alignment on the human hg19 reference genome identifies 234 novel exon-exon junctions. We recover all previously known UGT1 and UGT2 enzyme-coding transcripts and identify over 130 structurally and functionally diverse novel UGT variants. We further expose a revised genomic structure of UGT loci and provide a comprehensive repertoire of transcripts for each UGT gene. Data also uncover a remodelling of the UGT transcriptome occurring in a tissue-and tumor-specific manner. The complex alternative splicing program regulating UGT expression and protein functions is likely critical in determining detoxification capacity of an organ and stress-related responses, with significant impact on drug responses and diseases.
INTRODUCTION
One of the most significant metabolic defenses against a variety of structurally unrelated and potentially toxic molecules of both endogenous and exogenous sources, including drugs of all classes, relates to glucuronidation catalyzed by UDP-glucuronosyltransferases (UGT). In humans, 19 UGTs are encoded by 10 genes for which alternative splicing significantly expands the coding capacity and biological functions.
1,2 UGT enzymes deactivate and detoxify small molecules containing a nucleophilic functional group by conjugating the sugar moiety of the co-substrate uridine diphospho-glucuronic acid (UDPGA) to the lipophilic substrate. The resulting glucuronide product has increased water solubility, thus facilitating its excretion through bile and urine. This major conjugating phase II reaction is involved in the inactivation of 430% drugs currently used in the clinic, and is also key to the maintenance of cellular homeostasis of numerous biologically active endogenous molecules. 2 The UGT membrane proteins are classified into two major families UGT1 and UGT2 (subdivided in UGT2A and UGT2B). The UGT1 family members are encoded by a single gene located on chromosome 2q37.1, while nine distinct genes located on chromosome 4q13.2 define UGT2A and UGT2B proteins ( Figure 1 ) that share highly similar sequences ( Figure 2 ). 3 Sequence divergence is mostly located in the first and/or second exons, which encode the substrate binding domain, thus providing substrate specificity, while the other exons code for the conserved UDPGA binding and transmembrane domains. 1, 4 UGT genes are highly polymorphic and the genetic contributors (for example, polymorphisms and copy-number variations) to the significant interindividual UGT-mediated metabolism have been well documented. 2, [5] [6] [7] Pharmacogenomics studies focusing on associations between interindividual genetic differences and clinical drug responses have highlighted UGTs as key pharmacogenes associated with altered efficacy and risk of adverse events induced by drug treatments. 2, 6, 7 Recent studies reveal that a large number of alternative transcripts are produced from certain UGT genes in a tissue-specific manner, creating varied levels of expression and enzyme activity among individuals with potentially important clinical implications relative to response to drugs and diseases. 1, [8] [9] [10] [11] [12] [13] [14] [15] For instance, more than 20 novel UGT2B7 alternative transcripts were observed in the kidney, whereas novel UGT2B4 alternative isoforms were identified in liver samples. 9, 10, 15 Our previous work also indicates that alternative UGT transcripts encoding C-terminal truncated isoforms are expressed in various human tissues and exert an antagonistic function by negatively modulating UGT enzyme activity through protein-protein interaction. 1, 8, 14, 15 This led our group and others to suggest that most if not all human UGT genes exploit alternative splicing as a mean to expand protein diversity and potential biological functions while generating variability in expression of enzyme-coding transcripts. 1, 2, [16] [17] [18] The aim of this study was to establish the transcriptome landscape of human UGT genes in the most relevant metabolic tissues with regards to the predominant functions of UGT enzymes in drug and sex-steroid hormone metabolism. However, investigating these pharmacogenes using next-generation sequencing technologies is challenging, 19, 20 owing to the highpolymorphic nature, 2 the high sequence identity reaching up to 97% and the proximity of these genes within the UGT loci (Figures 1 and 2 ). We applied next-generation RNA sequencing (RNA-Seq) to collections of UGT mRNAs captured with UGTspecific designed probes from pools of drug-metabolizing (DM) tissues including the liver, kidney, intestine and colon, as well as hormone-dependent (HD) tissues comprising the prostate, breast and uterus. Normal and tumoral DM and HD tissue pools from at least three individuals per organ type were examined to establish the first comprehensive transcriptome of this important family of pharmacogenes in human tissues relevant to drug and sex-steroid hormone metabolism.
MATERIALS AND METHODS
The normal and tumoral DM tissues liver, kidney, small intestine and colon were purchased from Origene (Rockville, MD, USA). Normal and tumoral HD tissues consisted of described endometrial and breast tissues 21 as well as prostate tissues 22 obtained from Clontech (Mountain View, CA, USA). Participants provided written consent and the local research ethics committee approved the research. Each tissue type consisted of a pool of three individuals, whereas the commercial normal prostate sample consisted of a pool of 12 individuals. Total RNA was extracted using TRI Reagent (Sigma-Aldrich, Oakville, ON, Canada) and treated with RNeasy Figure 1 . Genomic organization of UGT loci. (a) Top: the UGT1 locus on chromosome 2 is characterized by multiple alternative first exons (light blue boxes), three central common exons and two alternative 3′ exons (dark blue boxes). Pseudo first exons are represented by green boxes. The encoded nine alternative classical UGT1A mRNA variants v1 (5′ variants mRNAs) are named according to the first exon. Bottom: detailed genomic organization of the UGT1 locus in the 3′ region and mRNAs produced by alternative splicing of 3′ exons 5a and 5b. The classical variants v1 comprise the 3′ exon 5a. Alternative splicing of 3′ exons 5b and 5a produces 18 additional 3′ mRNA variants v2 and v3. Pseudo first exons may be transcribed but are unlikely translated owing to internal deletions. (b) Top: the UGT2 locus on chromosome 4 comprises nine distinct genes (blue boxes), each mainly constituted of six exons, and six pseudo genes (green boxes). Sense of gene transcription is indicated by a blue arrow. Bottom: the UGT2B17 gene is detailed as an example, showing the six classical exons (boxes numbered 1-6) and sense of transcription (arrow) as well as the corresponding transcribed classical mRNA. Alternative splicing is known for UGT2A3, UGT2B7, UGT2B4 and UGT2A1/2A2 but not shown for sake of clarity. Below each genomic locus, regions targeted by probe tiling arrays for capture and enrichment of UGT sequences are identified by a black arrow. The targeted regions measure 1.53 Mbp and span chromosome 2 from 234 440 000 to 234 732 000 and chromosome 4 from 69 330 858 to 70 568 905 (coordinates of hg19 human reference genome).
MinElute Cleanup kit with DNase I (Qiagen, Toronto, ON, Canada). RNA concentrations were measured with Nanodrop ND-1000 (ThermoScientific, Ottawa, ON, Canada), and RNA quality was assessed using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Samples used had an RNA integrity number (RIN) between 7.4 and 9.1.
Equivalent amounts of total RNA from each tissue type were combined to generate pools of normal DM (DM-N), normal HD (HD-N), tumoral DM (DM-T) and tumoral HD (HD-T) ( Figure 3 ). Poly(A) isolation and cDNA synthesis steps were conducted on each RNA pool (1 μg) with TruSeq RNA sample Preparation kit v2 (Illumina, San Diego, CA, USA). A GS FLX Titanium Rapid Library preparation kit was used including mechanical fragmentation with GS Rapid library Nebulizer (30 psi for 2 min), and 454 GS Rapid Library MID Adaptors. Capture was performed to enrich UGT sequences on bar-coded cDNA libraries pooled at equal amounts (2 μg total). NimbleGen SeqCap EZ Choice capture solution consisting of 2.1 M 50-105mer probes was designed using the NimbleDesign software (NimbleGen, Roche Applied Science, Laval, QC, Canada). Capture probes spanned genomic sequences of UGT1 and UGT2 loci including introns, intergenic sequences and 50 000 bp on each loci sides ( Figure 1 ). The capture of UGT-specific cDNAs was performed on each of the four cDNA libraries (DM-N, DM-T, HD-N and HD-T) using a described procedure. 23 In brief, each cDNA library was hybridized to SeqCap EZ Oligo pool (sequences specific to targeted loci) and capture oligo-cDNA fragment complexes were pulled down with capture beads. UGT enrichment was estimated following PCR amplifications using published strategies. 13, 14, 24 GS FLX Titanium emPCR Kit (Life Sciences, Branford, CT, USA) was used with modifications in emPCR step reducing the number of cycles from 50 to 35. UGT-enriched cDNA pools were sequenced on a Roche GS FLX Titanium (Institut de Biologie Intégrative et des systèmes (IBIS), Laval University sequencing platform, Québec, QC, Canada). All sequence files generated by this project have been submitted to NCBI in the BioProject PRJNA258013. After trimming and quality control steps, reads were aligned on hg19 reference genome using both TopHat2 (v2.0.9) 25 and STAR (2.3.0). 26 The details regarding data analysis are provided as Supplementary Material. RT-PCR and Sanger sequencing validated selected transcripts. PCR reactions were performed with 10 ng cDNA in a final volume of 50 μl with 0.4-1 μM primers, 3 mM MgCl 2 , 200 mM dNTPs and 2 U AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA) (Primer pairs in Supplementary Table S1 ). The cycling conditions on a 9700 thermal cycler were 10 min at 95°C; 40 cycles at 95°C for 30 s, annealing at 60°C or 55°C for 30 s and elongation at 72°C for 1 min; final step at 72°C for 10 min.
RESULTS
Human UGT transcriptome analysis using RNA-Seq With the goal to uncover the most comprehensive transcriptome landscape of human UGT genes, four pools of normal and tumoral drug-metabolizing (DM-N and DM-T) (liver, kidney, intestine and colon) and hormone-dependent (HD-N and HD-T) tissues (breast, endometrium and prostate) were independently examined ( Figure 3 ). Quantitative PCR performed pre-and post-capture revealed up to 950-fold enrichment of UGT sequences before sequencing. High-throughput sequencing of libraries generated sequences ranging from 17 to 1652 nucleotides (nt) with a mean read length of 304 nt. Overall, 94% of sequenced reads mapped to the human genome with a coverage of 43 and 34% for UGT1 and UGT2 targets, respectively. UGT RefSeq exons were well represented with coverage ranging from 410-fold (UGT2A1-2A2 exon 6) to 7 × 10 5 -fold (UGT2B7 exon 1), in line with documented expression levels. 2 
Discovery of new exon-exon junctions
The strategy used to uncover new coding regions and splicing events is outlined in Figure 4 . Reads were aligned on the hg19 reference genome with TopHat2 and STAR. Overall, 1794 potential exon-exon junctions were identified. As the capture was designed to include 50 Kbp on either side of UGT1 and UGT2 loci, exon-exon junctions mapping to genes flanking the UGT loci were excluded from further analysis. Junctions arising from mismapping were also excluded after manual curation, taking into account UGT genetic variants according to the dbSNP database (build 138). Of the 518 junctions persisting after the filtering steps, 333 were successfully validated in silico ( Figure 4 ). These comprise 99 exonexon junctions reported in the literature, including 80 described in UCSC Genes tracks of which 60 are contained in RefSeq, confirming the effectiveness of our approach. Overall, 131 exon-exon junctions encompassing UGT genes and 103 in intergenic UGT regions, including some corresponding to known UGT2B pseudogenes, characterize the 234 novel exon-exon junctions. Of these 234 junctions, 25 are included in a large set of known and predicted splicing events at the UGT loci extracted from three Figure 2 . High sequence identity among the human UGT genes. The canonical nucleotide coding sequence of each UGT gene was retrieved from the NCBI RefSeq database (accession number is given for each mRNA, retrieved 04/01/2014). The percentage of identity was determined by pairwise alignments of UGT1 and UGT2 using the Clustal-W algorithm (emboss-emma). Lower right: percent identity between the nucleotide sequences of alternative UGT1 first exons is given to better reflect relationships among the UGT1A variants since they share four common 3′ exons.
different databases (Ensembl Gene Predictions (Release 75), Spliced ESTs and mRNA from GenBank).
The wide range of new exon-exon junctions reveals multiple types of novel UGT splicing events (Figure 5a ). New junctions were classified into six categories according to the type of predicted alternative transcripts with respect to the canonical variants, including a category best described as complex variants arising from multiple novel events. Most frequent events include splice shifts (21%), new terminal exons (42%), new internal exons (15%), exon skipping events (14%) and intronization (8%) (Figure 5a ). We also classified the 131 new exon-exon junctions in four categories according to splice site positions: novel splice donor site (5ʹ) (30%), novel splice acceptor site (3ʹ) (29%), novel splice donor and acceptor sites (27%) and a new combination of known donor and acceptor splice sites (14%) (Figure 5b) .
A comparison of junctions identified among normal and tumoral tissues, as well as between DM and HD tissue groups, reveals an unequal distribution of novel exon-exon junctions across the tissue pools ( Figure 6 ). For instance, only 3% of the 131 novel splicing events are common to the four pools (DM and HD, normal and tumor origins). Most novel junctions are specific to the DM tissue pools (n = 109), of which many are unique to the normal (n = 43) or tumor (n = 24) tissues (Figure 6a ), whereas eight junctions are specific to the HD tissue pools.
Novel UGT transcripts Findings drastically expand the coding potential of human UGT loci and the UGT transcriptome. The revised genomic organization of UGT loci comprising novel UGT coding regions is summarized in Figure 7 . New exons were discovered for each UGT gene. Long reads frequently encompassing several exon-exon junctions with some reads comprising up to six junctions has enabled transcript reconstruction. Over 132 novel alternative UGT transcripts are predicted. On the basis of the predicted sequences of novel alternative transcripts, only 10% lack an open reading frame (ORF). The transcripts involving predicted ORFs encoding UGT-related sequences are truncated in the 5ʹ (28%) or 3ʹ (33%) ends, whereas others (30%) contain either the loss or gain of internal coding sequences. . Bioinformatics analysis of UGT sequencing reads identifies over 230 novel UGT exon-exon junctions. Splicing events were identified after extensive analysis of reads according to criteria detailed in Methods using two splice-aware aligners (TopHat2 and STAR). The UCSC database (hg19.knownGene table) and custom scripts were used to extract, classify and identify known and potentially new splicing events. Among the 333 in silico-validated junctions detected by 1 to 382 reads, 40% were found by using both TopHat2 and STAR softwares, 50% by using STAR only and 10% by using TopHat2 only. This bioinformatics workflow identifies 99 UGT exon-exon junctions previously described in published literature and RefSeq (NCBI) and 131 novel UGT junctions further characterized in this study. Details of data processing, mapping and validation of splice junctions are given in the Methods section and Supplementary Material.
A comprehensive repertoire of all UGT transcripts is provided, including canonical UGT transcripts and novel predicted transcripts, derived from the single UGT1 gene (Supplementary Figure S1 ) and from UGT2 loci (Supplementary Figure S2) . UGT1 and UGT2B7 genes have the most extensive complexity, with 15 new exons (for a total of 33 exons for UGT1) and 7 new exons (total of 19 exons for UGT2B7). On the basis of our observations, a UGT2 gene encodes from 4 to 44 transcripts, whereas the UGT1 locus encodes over 65 potential transcripts (Supplementary Figures S1 and S2) . The novel putative transcripts mapping to the UGT1 locus are predominantly characterized by variable 5ʹ regions with no additional alternative events observed at the 3ʹ end of the loci relative to previous reports (Supplementary Figure S1 ). 8, 14 The high diversity of variants derived from a single UGT2 gene has already been highlighted for the UGT2B7 gene for which 22 transcripts have recently been documented after extensive molecular laboratory work. 10, 13, 15 Still, our RNA-Seq approach increases the UGT2B7 transcriptome to 44 transcripts. The exon counts for this gene now extends to 19 instead of 6 exons as currently described (Supplementary Figures S2b and 7) . A prominent category of UGT2 variants arises from skipping of internal exons. Exon-exon junctions predicting the existence of truncated UGT2As and every UGT2B (except UGT2B11) transcripts lacking exon 3 ( Supplementary Figures S2a-i) , exons 4-5 (observed for UGT2B10, UGT2B15, UGT2B17 and UGT2B28) or exon 5 (observed for UGT2B4 and UGT2B10) were identified (Supplementary Figure S2a and S2c-f). Several other variants further present either novel 5ʹ exons (UGT2A1 and UGT2B17) or 3ʹ exons (UGT2B4, UGT2B10 and UGT2B28), mostly contributing to extended 5ʹUTRs or 3ʹUTRs, but in some cases providing additional coding sequence (UGT2B4, UGT2B10 and UGT2B28) (Supplementary Figures S2a, S2c and S2f). Intronization of parts of exon 1, which may be also combined with a splice shift, is observed for UGT2B4, UGT2B7, UGT2B11, UGT2B15, and UGT2B17, occasionally preserving the ORF (Supplementary  Figures S2a, S2b , S2d-f). Our study also predicts many novel UGT2A3 variants arising from a splice shift in exon 1 and/or novel internal exons (Supplementary Figure S2i) . Lastly, findings further indicate that several UGT intergenic regions and pseudogenes, especially UGT1A2p and UGT2B27p, are transcribed (data not shown).
Examples of novel UGT transcripts One class of novel UGT1A transcripts with potentially important biological consequences lacked exon 2, common to all UGT1 enzymes ( Figure 8 and Supplementary Figure S1 ). Exon-exon junctions linking exons UGT1A1, UGT1A4, UGT1A6, UGT1A9 and UGT1A10 with the common exon 3 lead to variant transcripts named UGT1A_Δex2, and, in each case, the ORF of the corresponding UGT1 is preserved. These variants were observed predominantly in normal DM tissues (Figure 6b) . Experimental validation by RT-PCR amplification of the UGT1A1_Δex2 transcript was successfully conducted using RNA from several DM tissues (Figures 8a and b) . Remarkably, our study predicted transcripts in which the corresponding region encoded by exon 3 for UGT2 products is also missing (Δex3) for UGT2As, UGT2B15 and UGT2B17 (Supplementary Figures S2 and 8E ), indicating that this type of variant, characterized by the absence of the same protein domain, is common to most UGT1 and UGT2 genes. Expression of UGT2B17_Δex3 was successfully validated using a pool of DM tissues (Figures 8c and d) . The deleted region codes for 44 amino acids at the interface between substrate and co-substrate binding domains (Figure 8e) .
Of particular interest, a novel UGT2B7 variant that contains sequences from a new exon located in intron 2 (defined as exon 2b) was observed from multiple tissues (Figure 6b ). Inclusion of this exon extends the coding sequence by 96 nt at the junction of the substrate and co-substrate binding domains without altering the ORF-encoding sequences ( Figure 9 ). Sequences encompassing this novel exon 2b of UGT2B7 were successfully amplified and sequenced from DM tissues. This coding region is not observed for any other UGT transcript.
DISCUSSION
This study establishes the first comprehensive human UGT transcriptome in multiple normal and tumoral drug-metabolizing and hormone-dependent tissues. Using targeted RNA-Seq, we uncover the extensive variety of transcripts arising from alternative pre-mRNA splicing at the UGT1 and UGT2 genomic loci. This reveals an unprecedented remodeling of the UGT transcriptome likely occurring in an organ and tumor-specific manner. The revised genomic organization of UGT loci comprises numerous novel UGT-coding regions, and exemplifies their transcriptional diversity and complex regulation (Figure 7) . Data further emphasize that this post-transcriptional RNA processing allows UGT genes to produce multiple transcripts and regulates the complexity of these protein products that differ structurally and functionally. This mode of regulation is expected to significantly contribute to the interindividual variability of UGT-dependent detoxifying pathways, thereby potentially having pharmacological, pathological and toxicological implications.
To comprehensively establish the UGT alternative splicing landscape, our work involved a number of experimental and bioinformatics tools that allowed reaching an unprecedented depth. These included an RNA capture step targeting specifically UGT1 and UGT2 transcripts to enrich UGT mRNAs. Undeniably, the high levels of sequence identity and dense genetic variability found within UGT loci represent the most important challenge. 19, 20 Large-scale parallel pyrosequencing, a technology providing longer reads that encompass several exon-exon junctions, coupled to the use of two mapping softwares as well as a well-defined manual curation process have collectively greatly enhanced the precise assignment of reads to the appropriate UGT loci and transcript reconstruction. However, we cannot exclude that some of the less-frequent exon-exon junctions arise from mapping errors. Consistent with findings of previous laborious-targeted approaches, 9, 10, 14, 15, 18, 27, 28 all reported alternative UGT exons and transcripts were identified, validating the robustness of our approach. Overall, this study reports nearly 300 transcribed variants encoded by the 10 human genes, well beyond the suspected complexity already hinted by previous studies. Data highlight that a wide variety of alternative variants are generated from this small set of 10 UGT genes with an average potential of 22 transcripts per gene, which remain for the most part to be experimentally validated. Findings support organspecific expression patterns with an unequal distribution of novel exon-exon junctions across the tissue pools and only a small fraction of all splicing events common to all four pools of tissues ( Figure 6 ). Consistent with our observations, cancer and other diseases have been associated with dysregulated alternative splicing, including for several UGT genes. 12, 13, 15, [29] [30] [31] In addition, coordinated temporal control of alternative splicing has been recently documented for UGT2B7 in the kidney. 15 As extended read lengths were obtained with the use of pyrosequencing, and applied to pools of drug-or hormone-metabolizing tissues, our approach did not allow to quantitatively assess variant expression levels in specific tissues. This comprehensive definition of the most complete UGT transcriptome landscape reported here is, however, an instrumental prerequisite to the assessment of UGT variant expression by quantitative approaches, such as RNA sequencing often producing shorter reads mapping to multiple sites on highly similar loci such as those of pharmacogenes.
The novel UGT variants are structurally and functionally diverse and can be categorized in four groups: alternative 5′ exon(s), alternative 3′ exon(s), skipped exon(s) and exon gain (Table 1) . Data expose that nearly all UGT genes comprise alternative 5′ and 3′ exons and highlight that skipping of internal exons is also a common feature shared by most UGTs (Supplementary Figures S1  and S2) . Our previous functional studies support that a major function for C-terminal truncated alternative UGT isoforms is to Figure 6 . Distribution of novel exon-exon junctions in human tissue pools. (a) The total number of novel exon-exon junctions for which reads were detected in each tissue pool is given. The subset of novel junctions uniquely detected in the specified tissue pool is also represented (black). (b) Representative novel transcripts from new exon-exon junctions and their observed tissue pool distribution. Black boxes indicate that reads were detected for the corresponding exon-exon junctions, labeled as in Figure 7 . Novel predicted variants are named as in Supplementary Figures S1 and S2 . DM, drugmetabolizing tissues; HD, hormone-dependent tissues; N, normal; T, tumoral. Figure 7 . Revised genomic organization of UGT loci based on this study. The schematic representation of UGT loci includes classical exons (dark blue boxes) as originally described for the UGT1 locus, 33 the UGT2A locus 18, 28 and the UGT2B locus. 9, 10, 27 Recently described novel exons for UGT1A, 8,14 UGT2B4, 9 UGT2B7 10 are represented by light blue boxes. The new exons discovered by this RNA-Seq study are shown as red boxes, and novel splice sites extending previously described exons are shown as dashed gray boxes. Exon sizes are given above each box and intron sizes are given below dashed lines (nucleotides). (a) The alternative exons 1 of the UGT1 locus are numbered in italics according to the encoded UGT1A isoform. Classical exons and alternative 3′ exons common to all isoforms are tagged with standard numbers. Pseudo exons 1 are shown as gray boxes. (b) The seven UGT2B genes are aligned according to the six classical exons. Alternative novel exons described recently for UGT2B4 and UGT2B7 (light blue boxes) are also indicated with their published numbers. Novel exons and/or novel splice sites extending previously described exons have been identified for most UGT2B genes by the current RNA-Seq study. (c) The UGT2A genes include six classical exons (two alternative first exons for UGT2A1/2A2 and five common exons). For a given UGT, mature mRNA transcripts are produced by the alternative splicing of the shown exons. A detailed representation of all transcripts previously described and novel transcripts predicted by this RNA-Seq study is provided in Supplementary Figures S1 and S2 . Novel 5′ and 3′ terminal exons identified in this study may be longer than shown. Their actual size is based on the RNA-Seq data.
Unravelling the transcriptome of UGTs by targeted RNA-Seqregulate glucuronidation activity mediated by protein-protein interactions with UGT enzymes. 9, 13, 15, 32 This novel regulatory mechanism significantly modifies glucuronidation activity and impacts cellular response to drugs. 11 In turn, the use of alternative 5′ exons and promoters is well established as a mechanism allowing substrate specificity of UGT enzymes and regulation of their tissue-specific expression. 33, 34 However, this mechanism may also serve to regulate UGT enzyme activity. 8, 10, 13, 14 One example is UGT2B7 encoding nearly 45 putative transcripts. Many of these contain various lengths of 5′UTR driving the expression of alternative isoforms excluding the classical exon 1 that codes for the substrate-binding domain. 10 A reduced abundance of transcripts encoding UGT2B7 enzyme in favor of 5′ alternative isoforms was shown to provoke a considerable reduction of the glucuronidation potential. This phenomenon has been observed in the kidney with a shift toward functional enzyme on maturation of fetal to adult tissues and reversal of this process in neoplastic kidney samples, 13 demonstrating a cancer-specific switch in UGT2B7 alternative splicing patterns and a dynamic change during differentiation.
One particularly common type of novel variants exposed here involves an exon loss in both UGT1 (Δex2) and UGT2 (Δex3) transcripts arising from alternative splicing events at the boundary between exons encoding substrate and co-substrate binding domains (Figure 8 ). This spliced-out 44-amino-acid protein region is highly conserved among the UGT family members. Further validation of their expression in DM tissues supports their potential biological relevance and warrants in-depth functional analyses. This exon-skipping event might result in the production of alternative proteins with impaired glucuronidation activity but with regulatory function on glucuronidation, as recently observed for UGT2A1/UGT2A2_Δex3 variants. 18, 28 Alternative splicing may also lead to the inclusion of a novel protein region, as observed for the novel UGT2B7_ex2b variant (Figure 9 ). This UGT2B7 variant presents a new protein region of 32 amino acids exclusively detected in DM tissues. The location of this peptide sequence is at the boundary of substrate and co-substrate binding domains (as for internally truncated alternative UGT isoforms described above) Figure 9 . The novel variant UGT2B7_ex2b is expressed in drug-metabolizing tissues. (a) Schematic representation of the UGT2B7 gene. Classical (UGT2B7_v1) and novel (UGT2B7_ex2b) mRNA variants are represented with the PCR strategy designed to detect the expression of UGT2B7_ex2b. Primer p8 is specific to the novel exon 2b. (b) RT-PCR detection of UGT2B7_ex2b in a pool of total RNA from normal drugmetabolizing (DM) tissues comprising liver (L), small intestine (SI), colon (C) or kidney (K) and in individual tissues. Expression of the classical variant in these tissues has been reported. 10 (c) Schematic representation of the canonical UGT2B7 enzyme and the predicted UGT2B7 protein encoded by UGT2B7_ex2b. UGT2B7 functional protein regions are indicated as in Figure 8 . The nucleotide sequence of the novel exon 2b with flanking intronic sequences, in which splicing donor and acceptor sites are highlighted (bold) as well as the corresponding amino-acid sequence encoded by exon 2b, is given. and highlights that this region is particularly exposed to variability. Comparison of the exon 2b sequence with the corresponding intronic sequences of other human UGT2B genes indicates a conservation of the sequences, whereas the ORF is not preserved (Supplementary Figure S3) , and sequence comparisons predict that similar sequence conservation prevails among UGT2B orthologs from primates (data not shown).
The biological significance of novel predicted transcripts remains to be elucidated by various approaches. Previous research works on alternative UGT transcripts have repeatedly demonstrated the significant biological impact of alternate isoforms on glucuronidation, even those found at a lower abundance compared with the canonical UGT enzyme. 10, 11, 15, 32, 35 The clinical impact of minor variants of other gene products such as BRCA1/2 and the androgen receptor on breast and prostate cancers, respectively, is also convincingly documented. 36, 37 These previous reports, therefore, warrant in-depth evaluation of the novel predicted transcripts. Finally, a number of alternative UGT exons encode untranslated (UTR) sequences. A splicing-mediated generation of non-productive transcripts might also be a post-transcriptional regulatory mechanism (for example, by non-sense mediated decay and modulation of translation efficiency by upstream ORFs), 38, 39 therefore also having an impact on UGT expression levels critical for cell physiology. It is also anticipated that our results will help comprehend inconsistent mRNA and protein expression levels observed over the years and may therefore explain discrepancies in UGT mRNA quantification studies.
We conclude that alternative splicing is a major diversification mechanism of the human UGT transcriptome and proteome. The complex alternative splicing program regulating UGT expression and protein functions is likely critical in determining detoxification capacity of an organ and stress-related responses, with foreseen influence on drug responses and diseases. A better understanding of the UGT splicing program, its functional consequences and regulatory mechanism can provide new insights into metabolism and detoxification mechanisms for a large number of molecules of both endogenous and exogenous sources in many important normal and abnormal processes such as differentiation and cancer.
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